|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the recent update to the Oxford classification for allograft IgA nephropathy (IgAN), additional investigations on the clinical significance of the updated components are warranted.
|
31017369 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured the plasma metabolite levels in 12- and 22-week-old mice, prior to the manifestation of IgA nephropathy phenotypes, and statistically investigated the associations between these metabolites and the phenotypes of IgA nephropathy, such as the urine protein levels and histological phenotypes of the kidney at 32 weeks.
|
31291349 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We integrated eQTL data with an IgA Nephropathy (IgAN) GWAS to perform a transcriptome-wide association study (TWAS).
|
30057032 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the paraffin section of kidney biopsies from 40 chronic HBsAg carriers with membranous nephropathy (MGN), mesangiocapillary glomerulonephritis (MCGN) or IgA nephropathy (IgAN) for HBV DNA and HBV RNA using in situ hybridization (ISH).
|
8943480 |
1996 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed specimens from patients with diabetic nephropathy (DN), FSGS, IgA nephropathy (IgAN), membranoproliferative GN (MPGN) (<i>n</i>=19-23 for each disease), and a control group (<i>n</i>=14).
|
28663230 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed 574 IgA nephropathy (IgAN), 175 membranous nephropathy (MGN), and 177 focal segmental glomerulosclerosis (FSGS) cases from 3 Korean kidney centers.
|
29095250 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two recent genome-wide studies in IgAN have identified a major susceptibility locus on chromosome 6q22 (IGAN1) and two additional loci with suggestive linkage signals on chromosomes 4q26-31 and 17q12-22.
|
17634434 |
2007 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To identify novel biomarkers of IgA nephropathy (IgAN) through bioinformatics analysis and elucidate the possible molecular mechanism.
|
31392215 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This work is an immunohistochemical study of Ras expression in normal renal tissue and in membranous glomerulonephritis (MGN), IgA nephropathy (IgAN) and IgA-negative mesangioproliferative glomerulonephritis (MPGN).
|
14551355 |
2003 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the value of urinary angiostatin levels for assessing disease severity and progression of IgA nephropathy (IgAN).
|
30943905 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to evaluate the association between ABO blood group and progression of IgA nephropathy (IgAN).
|
29088730 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This included 401 patients with membranous nephropathy (MN), 824 patients with IgA nephropathy (IgAN), 385 patients with focal segmental glomerulosclerosis (FSGS), 397 patients with lupus nephritis (LN) and 399 patients with ANCA-related glomerulonephritis (ANCA-GN).
|
31113679 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There is controversy over whether IgA nephropathy (IgAN) and Henoch-Schönlein purpura nephritis (HSPN) are the same diseases.
|
31468231 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The study was conducted in 140 patients with primary chronic GN: mesangial proliferative GN (MesPGN) (n = 49), IgA nephropathy (IgAN) (n = 31), membranous nephropathy (MN) (n = 27), focal segmental glomerulosclerosis (FSGS) (n = 25), membranoproliferative GN (MPGN) (n = 4), and minimal change disease (MCD) (n = 4), and controls (n = 187).
|
23681285 |
2014 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum immunoglobulin A (IgA)/C3 ratio is considered to be an effective predictor of IgA nephropathy (IgAN).
|
31039758 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The serum fibrinogen level is closely related to inflammatory states, but its relationship to the prognosis of IgA nephropathy (IgAN) is unclear.
|
29228758 |
2017 |
|
IGA Glomerulonephritis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of FcalphaRIgamma in disease progression remains unknown, notably in IgA nephropathy (IgAN), one of major causes of end-stage renal disease, in which large amounts of circulating IgA-immune complexes (IC) may mediate receptor activation.
|
17393381 |
2007 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to investigate the association of plasma acylcarnitines with renal function and its alteration by intervention in patients with IgA nephropathy (IgAN).
|
30631376 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognosis of patients with allograft IgA nephropathy (IgAN) requires further investigation.
|
29718591 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prognosis of IgA nephropathy (IgAN) is very heterogeneous.
|
30445530 |
2018 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present work exploits modern methodology to estimate the total nephron number in glomerulopathies with prevalent proteinuria/nephrotic syndrome versus glomerulopathies with nephritic syndrome (IgA nephropathy (IgAN), lupus nephritis), thus extending previous observations about the number and function of glomeruli in different physiological and pathological states.
|
31534861 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The onset of IgA nephropathy (IgAN), characterized by glomerular deposition of IgA-containing immune complexes, is often associated with synpharyngitic hematuria.
|
31489594 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The efficacy and safety of glucocorticoids for the treatment of patients with IgA nephropathy (IgAN) remains controversial.
|
30843135 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The clinical course of IgA nephropathy (IgAN) varies from asymptomatic nonprogressive to aggressive disease, with up to one in four patients manifesting ESRD within 20 years of diagnosis.
|
30971457 |
2019 |
|
IGA Glomerulonephritis
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The clinical course of IgA nephropathy (IgAN) is variable and complement activation may predict prognosis.
|
28814945 |
2017 |